Probius, a deep-tech company focused on bridging the data gap between biology and AI, has announced it has secured $7.2 million in new investment capital. This funding round is set to advance the company's mission of illuminating new opportunities for biomedical research and healthcare practices by leveraging advanced technological integration.
The company's core work involves combining principles from physics, mathematics, and biological data to foster a new era of AI-enabled biological research and decentralized predictive healthcare. Probius aims to transform how biological insights are generated and applied, ultimately impacting patient care and scientific discovery. This latest investment builds upon a foundation of ten years of dedicated research and development, which previously received over $15 million in financial support from the Department of Defense and early-stage investors.
The $7.2 million in funding will be strategically deployed to accelerate the commercialization of Probius's revolutionary products. The company plans to use the capital for key growth initiatives, including scaling its operations, expanding its technological infrastructure, and bringing its innovative solutions to market. This investment signifies a crucial step in Probius's journey from extensive R&D to active market engagement.
With this significant capital infusion, Probius is positioned to further develop its offerings and expand its reach within the biomedical and healthcare sectors. The company anticipates that the successful deployment of its AI-enabled platforms will contribute to more precise and predictive healthcare solutions, driving its continued growth and impact in the coming years.
.png&w=3840&q=75)
